Evidence map›Paper›PMID 36255238›Full record

ArticlemBio2022

HPV-16 E7 Interacts with the Endocytic Machinery via the AP2 Adaptor μ2 Subunit.

Om Basukala, Oscar Trejo-Cerro, Michael P Myers, David Pim, Paola Massimi, Miranda Thomas, Corrado Guarnaccia, David Owen, Lawrence Banks

Open access · goldAbstract read
In one paragraph

Article in mBio, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Are HPV oncogenic viruses involved in salivary glands tumorigenesis?Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Om BasukalaInternational Centre for Genetic Engineering and Biotechnologygrid.425195.e, Trieste, Italy.ORCID 0000-0002-1404-2848
Oscar Trejo-CerroInternational Centre for Genetic Engineering and Biotechnologygrid.425195.e, Trieste, Italy.
Michael P MyersInternational Centre for Genetic Engineering and Biotechnologygrid.425195.e, Trieste, Italy.
David PimInternational Centre for Genetic Engineering and Biotechnologygrid.425195.e, Trieste, Italy.
Paola MassimiInternational Centre for Genetic Engineering and Biotechnologygrid.425195.e, Trieste, Italy.
Miranda ThomasInternational Centre for Genetic Engineering and Biotechnologygrid.425195.e, Trieste, Italy.
Corrado GuarnacciaInternational Centre for Genetic Engineering and Biotechnologygrid.425195.e, Trieste, Italy.
David OwenCambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.
Lawrence BanksInternational Centre for Genetic Engineering and Biotechnologygrid.425195.e, Trieste, Italy.ORCID 0000-0003-4360-5731
International Centre for Genetic Engineering and Biotechnology · ITUniversity of Cambridge · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human papillomavirus (HPV) E7 plays a major role in HPV-induced malignancy, perturbing cell cycle regulation, and driving cell proliferation. Major targets of cancer-causing HPV E7 proteins are the pRB family of tumor suppressors, which E7 targets for proteasome-mediated degradation and whose interaction is promoted through an acidic patch, downstream of the LXCXE motif in E7, that is subject to phosphorylation by casein kinase II (CKII). In this study we show that HPV-16 E7 targets the AP2-complex, which plays a critical role in cargo recognition in clathrin-mediated endocytosis. Intriguingly, HPV-16 E7 contains a specific amino acid sequence for AP2 recognition, and this overlaps the pRb LXCXE recognition sequence but involves completely different amino acid residues. HPV-16 E7 does this by binding to the AP2-μ2 adaptor protein subunit via residues 25-YEQL-28 within the LXCXE motif. Point mutations at Y25 within 22-LYCYE-26 suggest that the interaction of E7 with AP2-μ2 is independent from pRB binding. In cells, this interaction is modulated by acidic residues downstream of LXCXE, with the binding being facilitated by CKII-phosphorylation of the serines at positions 31 and 32. Finally, we also show that association of HPV-16 E7 with the AP2 adaptor complex can contribute to cellular transformation under low-nutrient conditions, which appears to be mediated, in part, through inhibition of AP2-mediated internalization of epidermal growth factor receptor (EGFR). This indicates that E7 can modulate endocytic transport pathways, with one such component, EGFR, most likely contributing toward the ability of E7 to induce cell transformation and malignancy. These studies define a new and unexpected role for HPV-16 E7 in targeting clathrin-mediated endocytosis.

Indexed as

Human papillomavirus 16Papillomavirus InfectionsAdaptor Proteins, Vesicular TransportCell Transformation, NeoplasticClathrinEndocytosisErbB ReceptorsHumansProtein BindingAdaptor Proteins, Vesicular TransportClathrinErbB ReceptorsAP2clathrinE7endocytosisHPV

Identifiers

PMID36255238
PMCPMC9765456
OpenAlexW4306732527

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.